RICARDO ROMITI
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/53 - Laboratório de Micologia, Hospital das Clínicas, Faculdade de Medicina
LIM/50 - Laboratório de Patologia das Moléstias Infecciosas, Hospital das Clínicas, Faculdade de Medicina
LIM/53 - Laboratório de Micologia, Hospital das Clínicas, Faculdade de Medicina
LIM/50 - Laboratório de Patologia das Moléstias Infecciosas, Hospital das Clínicas, Faculdade de Medicina
16 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 16
conferenceObject Patient perception and the importance of clear/almost clear skin as a treatment goal in moderate-to-severe plaque psoriasis: results of the 'Clear about Psoriasis' worldwide patient survey(2017) ARMSTRONG, A.; JARVIS, S.; BOEHNCKE, W-H; RAJAGOPALAN, M.; FERNANDEZ-PENAS, P.; ROMITI, R.; BEWLEY, A.; O'DONNELL, M.; HUNEAULT, L.; DEKKER, E.; SODHA, M.; WARREN, R. B.conferenceObject Discordance between patients with psoriasis and their physicians in assessing disease severity, psoriasis-related symptoms and disease control: Results from a large observational physician and patient survey(2017) GRIFFITHS, Christopher; NALDI, Luigi; AUGUSTIN, Matthias; ROMITI, Ricardo; GUEVARA-SANGINES, Esther; HOWE, Tanya; RICHARDSON, Craig; TIAN, Haijun; JO, Seong-Jin- Patient-dermatologist agreement in psoriasis severity, symptoms and satisfaction: results from a real-world multinational survey(2018) GRIFFITHS, C. E. M.; AUGUSTIN, M.; NALDI, L.; ROMITI, R.; GUEVARA-SANGINES, E.; HOWE, T.; PIETRI, G.; GILLOTEAU, I.; RICHARDSON, C.; TIAN, H.; JO, S. J.BackgroundPsoriasis is a chronic immune-mediated inflammatory disease, which often requires lifelong treatment. A strong partnership between the patient and healthcare practitioners should help to achieve effective treatment outcomes. ObjectiveTo assess concordance of views between patients with psoriasis and their treating dermatologists relative to psoriasis severity, presence of symptoms and satisfaction with disease control achieved. MethodsWe used data from the Growth from Knowledge (GfK) Disease Atlas real-world evidence program, a syndicated, retrospective, cross-sectional survey among dermatologists and their systemic therapy eligible patients with psoriasis, conducted across nine countries. Concordance was measured through patients and their dermatologist's identical answers to the same survey questions. Concordance was evaluated using percentage agreement between dermatologists and their patients, and Cohen's kappa () statistic. The level of concordance was defined as none' ( 0), none to slight' (0.01-0.20), fair' (0.21-0.40), moderate' (0.41-0.60), substantial' (0.61-0.80) and almost perfect' (>0.8). The analysis was conducted for the overall population and for each participating country. ResultsOverall, 524 dermatologists and 3821 patients with psoriasis were included in the survey. Concordance of patient and dermatologist perceptions of psoriasis severity was fair both at diagnosis, and at the time of the survey (61% agreement, = 0.326 and 55% agreement, = 0.370, respectively). Higher levels of concordance were reported when patients assessed their psoriasis as moderate-to-severe (using Investigator's Global Assessment/Physician's Global Assessment [IGA/PGA] 5-point scale of 3 or 4). Concordance regarding symptoms ranged from fair to moderate ( = 0.241-0.575). Satisfaction with psoriasis control was fair (39% agreement, = 0.213). Results showed different patterns of concordance across the participating countries although a low concordance was observed on the satisfaction with psoriasis control in all of them. ConclusionResults from this multinational real-world survey indicate different perceptions between patients with psoriasis and their dermatologist with respect to psoriasis severity, symptoms and disease control. Linked article: This article is commented on by P.V. Chernyshov, pp. 1404-1405 in this issue. To view this article visit
conferenceObject Psoriasis And Mental Health Comorbidities: A Multinational Analysis Using the Global Healthcare Study on Psoriasis (GHSP)(2023) PETERSON, Hannah; KOROURI, Edwin; KINGSTON, Paige; LEE, Kathryn; HUANG, Margaret; YEE, Danielle; AGUERO, Rosario; ARTIGA, Kevin; VALENZUELA, Fernando; ROMITI, Ricardo; DIDASKALU, Johannes; EGEBERG, Alexander; OON, Hazel H.; MAUL, Julia-Tatjana; ARMSTRONG, April W.- Comorbidities in Chilean patients with psoriasis: a Global Healthcare Study on Psoriasis(2022) VALENZUELA, Fernando; CRUZ, Claudia De La; LECAROS, Cristobal; FERNANDEZ, Javier; HEVIA, Gonzalo; MAUL, Lara Valeska; THYSSEN, Jacob P.; VERA-KELLET, Cristian; EGEBERG, Alexander; ARMIJO, Daniela; PIZARRO, Cristian; RIVEROS, Tatiana; CORREA, Hernan; GUGLIELMETTI, Antonio; DIDASKALU, Johannes A.; WU, Jashin J.; GRIFFITHS, Christopher E. M.; ROMITI, Ricardo; MAUL, Julia-TatjanaBackground Psoriasis is a chronic inflammatory skin disease associated with several important medical comorbidities. There are scant data available on the comorbidities of patients with psoriasis in South America. Aim To examine the comorbidity profile of adult patients with psoriasis in Chile and its association with severity of psoriasis. Methods This was a multicentre, cross-sectional study involving 16 hospitals and clinics in Chile, which used a 48-item questionnaire to study clinician- and patient-reported outcomes and comorbidities. Inferential analyses were performed by psoriasis severity, using Fisher exact test, Student t-test and multivariable logistic regression. Results In total, 598 adult patients with psoriasis were included (51.1% male; mean age 49.2 +/- 15.1 years); 48.5% mild and 51.4% moderate to severe; Psoriasis Area and Severity Index 11.6 +/- 11.5; body surface area 14.7 +/- 18.2%. Plaque psoriasis was the most common phenotype (90.2%), followed by guttate (13.4%). Psoriatic arthritis occurred in 27.3% of patients. Comorbidities were reported in 60.2% of all patients with psoriasis. Frequent concomitant diseases were obesity (25.3%), hypertension (24.3%), Type 2 diabetes mellitus (T2DM) (18.7%), dyslipidaemia (17.4%), metabolic syndrome (16.7%) and depression (14.4%). After adjustment, significant associations were found between moderate to severe psoriasis and obesity, T2DM and nonalcoholic fatty liver disease (NAFLD) compared with mild psoriasis. Conclusions We report a large study of comorbidities, including depression, dyslipidaemia, T2DM and NAFLD, in people with psoriasis in Chile. The prevalence of comorbidities with psoriasis in Chile appears similar to that found in Western countries, and emphasizes the importance of assessing patients with psoriasis for risk factors for and presence of, comorbid disease in a multidisciplinary setting.
conferenceObject PSORIATIC ARTHRITIS IS ASSOCIATED WITH A GREATER ECONOMIC AND HUMANISTIC BURDEN AMONG PATIENTS WITH PSORIASIS: RESULTS FROM A MULTINATIONAL PHYSICIAN AND PATIENT SURVEY(2016) ROMITI, R.; GRIFFITHS, C. E.; JO, S. J.; GUEVARA-SANGINES, E.; ROSE, A.; GILLOTEAU, I; FOX, T.; RICHARDSON, C.; TIAN, H.; NALDI, L.; AUGUSTIN, M.conferenceObject Greater burden of disease in systemic eligible psoriasis patients with anxiety and/or depression: Results from a large observational physician and patient survey(2017) NALDI, Luigi; GRIFFITHS, Christopher; JO, Seong-Jin; GUEVARA-SANGINES, Esther; ROMITI, Ricardo; HOWE, Tanya; RICHARDSON, Craig; TIAN, Haijun; AUGUSTIN, MatthiasconferenceObject PSORIASIS (PSO) PATIENTS' PROFILE AND IMPACT OF THE DISEASE ON PATIENTS' QUALITY OF LIFE AND WORK PRODUCTIVITY IN A REAL-LIFE SETTING IN BRAZIL(2017) LOPES, N.; PIETRI, G.; HOWE, T.; GILLOTEAU, I; TIAN, H.; PERTEL, P.; ROMITI, R.- A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey(2018) GRIFFITHS, C. E. M.; JO, S. -J.; NALDI, L.; ROMITI, R.; GUEVARA-SANGINES, E.; HOWE, T.; PIETRI, G.; GILLOTEAU, I.; RICHARDSON, C.; TIAN, H.; AUGUSTIN, M.Background Psoriasis is a chronic, immune-mediated disease, characterized by symptoms that include itching and skin pain and is often asssociated with comorbidities. Patients have a substantial detriment to quality of life (QoL) and work productivity with associated cost burden. Objectives To investigate the incremental burden of comorbidities, itch and affected body areas among systemic eligible patients with psoriasis, using a multinational survey of dermatologists and their patients with psoriasis. Methods Multinational data from the Growth from Knowledge (GfK) Disease Atlas Global Real-World Evidence program were used. Eligible patients were identified as those who were currently having or had ever had moderate-to-severe psoriasis, and must have been receiving prescription treatments at the time of the survey. Multivariable regression analyses were conducted to assess the incremental burden among psoriasis patients with physical and psychological comorbidities, itch and affected visible and sensitive body areas vs. psoriasis patients without these conditions, respectively. Results The study enrolled 3821 patients with psoriasis, from nine countries, with an average Psoriasis Area and Severity Index score of 6.4. The presence of comorbidities was associated with a significant increase in the likelihood of skin pain, lower QoL, greater work impairment and increased usage of medical resources (except in psoriasis patients with obesity and type 2 diabetes). Psoriasis patients suffering from itch and those with visible and sensitive affected body areas also had impaired QoL vs. those without these conditions. Conclusion Psoriasis patients with physical and psychological comorbidities, itch and affected visible and sensitive body areas had lower QoL and greater work impairment compared to those without these conditions.
- Patient perceptions of clear/almost clear skin in moderate-to-severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey(2018) ARMSTRONG, A.; JARVIS, S.; BOEHNCKE, W. -H.; RAJAGOPALAN, M.; FERNANDEZ-PENAS, P.; ROMITI, R.; BEWLEY, A.; VAID, B.; HUNEAULT, L.; FOX, T.; SODHA, M.; WARREN, R. B.Background Therapeutic advances have made the achievement of clear/almost clear skin possible for many patients with moderate-to-severe plaque psoriasis. Objective Methods To determine patient perceptions of the impact of psoriasis and of attaining clear/almost clear skin. Global survey of patients with moderate-to-severe psoriasis. Results Conclusion A total of 8338 patients from 31 countries participated. The majority (57%) had not achieved self-assessed clear/almost clear skin with their current therapy, and 56% of those who had not met this goal believed it would be impossible to do so. Among the patients who had clear/almost clear skin, 73% had not initiated their current treatment until >1 year after psoriasis diagnosis, and 28% had to wait >5 years. Eighty-four percent of all respondents experienced discrimination and/or humiliation due to psoriasis, and many reported negative effects on work, intimate relationships, sleep and mental health. Patients without clear/almost clear skin reported that such achievement would open new possibilities, such as swimming (58%), a wider choice of clothing (40%), and meeting new people (26%). A limitation of this study, as with any survey-based research, is that selection and recall bias may have been present. Additionally, respondent definitions of clear/almost clear skin were subjective and may have varied. Despite the importance of clear/almost clear skin to psoriasis patients, most are still not achieving it, and many are unaware it is possible.